Developing Costimulatory Molecules for Immunotherapy of Diseases

CHF 155.55
Auf Lager
SKU
DATQ1E86PVD
Stock 1 Verfügbar
Geliefert zwischen Di., 30.12.2025 und Mi., 31.12.2025

Details

*Developing Costimulatory Molecules for Immunotherapy of Diseases* highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation.

The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases.


Autorentext

Dr. Manzoor Ahmad Mir holds a Master's in Zoology from HNBG Central University and completed his Ph.D. in Immunology at Jawaharlal Nehru University, New Delhi, and CSIR-Institute of Microbial Technology, Chandigarh. His research focuses on cancer biology, combination therapy in breast cancer, and tuberculosis immunology. Dr. Mir has published over 50 high-impact research papers and book chapters. He has authored more than 15 books with international publishers of repute. He serves on the editorial boards of prestigious journals. He is a member of several scientific organizations, including the American Association of Cancer Research and the Royal British Society. He has received the TARE Fellowship and the SRFP-2019 from the Indian Science Academies. Dr. Mir teaches Cancer Biology and Immunology at the University of Kashmir, where he heads the Department of Bioresources.


Klappentext

Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation.

The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases.


Inhalt

Chapter 1: Introduction to costimulation and costimulatory molecules Chapter 2. Concept of reverse costimulation and its role in diseasesChapter 3. Costimulation immunotherapy in infectious diseasesChapter 4. Costimulation immunotherapy in allergies and asthmaChapter 5. Costimulation immunotherapy in lymphomas and cancerChapter 6. T cell costimulation and its applications in diseases

Weitere Informationen

  • Allgemeine Informationen
    • GTIN 09780128025857
    • Genre Technology Encyclopedias
    • Anzahl Seiten 322
    • Herausgeber Elsevier Science Publishing Co Inc
    • Größe H229mm x B152mm x T20mm
    • Jahr 2015
    • EAN 9780128025857
    • Format Kartonierter Einband
    • ISBN 978-0-12-802585-7
    • Veröffentlichung 27.05.2015
    • Titel Developing Costimulatory Molecules for Immunotherapy of Diseases
    • Autor Mir Manzoor Ahmad
    • Gewicht 540g
    • Sprache Englisch

Bewertungen

Schreiben Sie eine Bewertung
Nur registrierte Benutzer können Bewertungen schreiben. Bitte loggen Sie sich ein oder erstellen Sie ein Konto.
Made with ♥ in Switzerland | ©2025 Avento by Gametime AG
Gametime AG | Hohlstrasse 216 | 8004 Zürich | Schweiz | UID: CHE-112.967.470